As part of the distribution agreement, Arthrex will secure exclusive global distribution rights to Procellera Technology in the orthopaedic and sports medicine markets for both human and veterinary applications.

Vomaris Innovations president and CEO Michael Nagel said: "With the increasing market demand for non-pharmacologic solutions for infection prevention, improved post-operative outcomes and cost containment, the orthopaedic incision and wound care market has been a rapidly growing segment for us."

Vomaris will continue to take the responsibility for manufacturing and ongoing research and development, while responsibilities related to future orthopaedic development programmes will be shared between both firms.

Procellera Antimicrobial Wound Dressing features wireless advanced microcurrent technology, and provides solution for wound and incisional care with demonstrated broad-spectrum antimicrobial and anti-biofilm efficacy, noted Vomaris.

Operating in around 90 countries across the globe, Arthrex is involved in new product development and medical education in orthopaedics and sports medicine. Vomaris is specialized in microcurrent-generating solutions for the wound care market.